Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh purchased 250 shares of the stock in a transaction dated Tuesday, June 11th. The stock was purchased at an average price of $107.01 per share, for a total transaction of $26,752.50. Following the completion of the acquisition, the director now directly owns 61,703 shares in the company, valued at approximately $6,602,838.03. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jason Aryeh also recently made the following trade(s):

  • On Wednesday, May 29th, Jason Aryeh purchased 250 shares of Ligand Pharmaceuticals stock. The stock was purchased at an average price of $111.01 per share, for a total transaction of $27,752.50.
  • On Friday, May 31st, Jason Aryeh purchased 1,000 shares of Ligand Pharmaceuticals stock. The stock was purchased at an average price of $109.51 per share, for a total transaction of $109,510.00.
  • On Monday, May 20th, Jason Aryeh purchased 250 shares of Ligand Pharmaceuticals stock. The stock was purchased at an average price of $112.01 per share, for a total transaction of $28,002.50.
  • On Tuesday, May 14th, Jason Aryeh purchased 250 shares of Ligand Pharmaceuticals stock. The stock was purchased at an average price of $112.51 per share, for a total transaction of $28,127.50.

Ligand Pharmaceuticals stock traded up $2.70 during trading on Wednesday, reaching $110.33. The company had a trading volume of 223,600 shares, compared to its average volume of 556,581. Ligand Pharmaceuticals Inc. has a 1-year low of $98.56 and a 1-year high of $278.62. The stock has a market capitalization of $2.12 billion, a P/E ratio of 17.57, a P/E/G ratio of 2.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.57, a quick ratio of 8.33 and a current ratio of 8.39.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported $1.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.28. Ligand Pharmaceuticals had a net margin of 320.12% and a return on equity of 19.21%. The firm had revenue of $43.48 million for the quarter, compared to analysts’ expectations of $38.28 million. During the same quarter last year, the company earned $1.55 EPS. The firm’s revenue for the quarter was down 22.6% compared to the same quarter last year. Sell-side analysts predict that Ligand Pharmaceuticals Inc. will post 2.34 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in LGND. Coastal Investment Advisors Inc. acquired a new stake in Ligand Pharmaceuticals in the 1st quarter valued at $25,000. Manchester Capital Management LLC acquired a new stake in Ligand Pharmaceuticals during the 1st quarter worth $26,000. Rockefeller Capital Management L.P. boosted its stake in Ligand Pharmaceuticals by 294.4% during the 1st quarter. Rockefeller Capital Management L.P. now owns 213 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 159 shares during the last quarter. Pearl River Capital LLC acquired a new stake in Ligand Pharmaceuticals during the 4th quarter worth $41,000. Finally, FinTrust Capital Advisors LLC boosted its stake in Ligand Pharmaceuticals by 64.4% during the 1st quarter. FinTrust Capital Advisors LLC now owns 337 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 132 shares during the last quarter.

A number of analysts have recently weighed in on the stock. BidaskClub cut shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. Argus set a $140.00 price target on shares of Ligand Pharmaceuticals and gave the company a “buy” rating in a report on Monday. Zacks Investment Research cut shares of Ligand Pharmaceuticals from a “buy” rating to a “strong sell” rating in a report on Wednesday, March 27th. ValuEngine cut shares of Ligand Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 26th. Finally, Barclays assumed coverage on shares of Ligand Pharmaceuticals in a report on Tuesday. They issued an “equal weight” rating and a $131.00 price target on the stock. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $195.88.

COPYRIGHT VIOLATION WARNING: This story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.dailypolitical.com/2019/06/12/ligand-pharmaceuticals-inc-nasdaqlgnd-director-jason-aryeh-purchases-250-shares.html.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Read More: The risks of owning bonds

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.